Compounds > p-Aminosalicylic acid methyl ester
Page last updated: 2024-11-06

p-Aminosalicylic acid methyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID77787
CHEMBL ID1458862
CHEBI ID35089
SCHEMBL ID616715

Synonyms (62)

Synonym
AC-7219
nsc 30263
brn 0972631
nsc 48927
benzoic acid, 4-amino-2-hydroxy-, methyl ester
methyl p-aminosalicylate
pas methyl ester
einecs 223-958-3
salicylic acid, amino-, methyl ester
4-14-00-01973 (beilstein handbook reference)
smr000126643
MLS000544886
methyl 4-amino-2-hydroxybenzenecarboxylate
nsc-48927
nsc48927
nsc30263
4136-97-4
nsc-30263
p-aminosalicylic acid methyl ester
BIONET2_000475
methyl 4-amino-2-hydroxy-benzoate
4-aminosalicylic acid, methyl ester
OPREA1_010221
HMS1365F13
AKOS005069412
methyl 4-amino-2-hydroxybenzoate
NCGC00246577-01
methyl 4-aminosalicylate
A825536
HMS2313B05
FT-0600644
11P-706
AM20060979
SCHEMBL616715
mfcd00088091
SY005181
methyl 2-hydroxy-4-aminobenzoate
4-amino-2-hydroxy benzoic acid methyl ester
3-hydroxy-4-methoxycarbonylaniline
4-aminosalicyclic acid methyl ester
methyl 4-amino-salicylate
methyl 4aminosalicylate
4-amino-2-hydroxy-benzoic acid methyl ester
QQOXBFUTRLDXDP-UHFFFAOYSA-N
p-aminosalicylsauremethylester
CHEBI:35089 ,
methyl4-aminosalicylate
W-106307
4-aminosalicylic acid methyl ester
CHEMBL1458862
CS-W017842
4-amino-2-hydroxybenzoic acid methyl ester
M2699
DTXSID80194310
D71082
methyl4-amino-2-hydroxybenzoate
Z276846542
4-amino-2-hydroxybenzoic acid methylester
Q27116408
EN300-177151
2-hydroxy-4-aminobenzoic acid methyl ester
KKK6HU29FV

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" para-Aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant Mycobacterium tuberculosis, has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day, which in turn causes severe gastrointestinal disturbances presumably by disruption of gut microbiota and host epithelial cells."( Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022)		0.72

Dosage Studied

ExcerptRelevanceReference
" Among the mono-fluorinated analogs prepared, 5-fluoro-PAS, exhibited the best activity and an 11-fold decreased rate of inactivation by NAT-1 that translated to a 5-fold improved exposure as measured by area-under-the-curve (AUC) following oral dosing to CD-1 mice."( Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency12.58930.036619.637650.1187AID1466; AID2242
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58933.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58933.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1879678AUC in CD-1 mouse plasma assessed as para-aminosalicylic acid AUC at 10 mg/kg, po administered as single dose and measured up to 5 hrs by HPLC-MS/MS analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1879681AUC in CD-1 mouse at 10 mg/kg, po administered as single dose and measured up to 5 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1879677Metabolic stability in human plasma assessed as parent compound remaining at 1 ug/ml measured after 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1879685Ratio of compound AUC to para-aminosalicylic acid AUC in CD-1 mouse2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1879679Metabolic stability in CD-1 mouse plasma assessed as parent compound remaining at 1 ug/ml measured after 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
AID1879684Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 10 days by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.4110carbohydrazideantitubercular agent;
drug allergen
aminosalicylic acid
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.		2.4110aminobenzoic acid;
phenols		antitubercular agent
linezolid
[no description available]		2.4110acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
4-azidosalicylic acid
4-azidosalicylic acid: structure given in first source		2.4110
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Tuberculosis, Drug-Resistant
[description not available]		02.4110
Koch's Disease
[description not available]		02.4110
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		02.4110
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		02.4110